WO1998004279A1 - Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxiethyl)-rapamycin - Google Patents
Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxiethyl)-rapamycin Download PDFInfo
- Publication number
- WO1998004279A1 WO1998004279A1 PCT/EP1997/004123 EP9704123W WO9804279A1 WO 1998004279 A1 WO1998004279 A1 WO 1998004279A1 EP 9704123 W EP9704123 W EP 9704123W WO 9804279 A1 WO9804279 A1 WO 9804279A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rapamycin
- cyclosporin
- hydroxyethyl
- transcription inhibitor
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the invention thus provides products and methods for co-administration of an IL-2 transcription inhibitor (e.g., cyclosporin A or FK506) and 40-O-(2-hydroxyethyl)-rapamycin, especially cyclosporin A and 40-O-(2-hydroxyethyl)-rapamycin, at synergistically effective dosages, e.g.,
- compositions under 6 above also include compositions suitable for topical administration e.g., in the form of a dermal cream, ointment, gel or like preparation, especially in combination or association with penetration enhancing agents, e.g., for the treatment of autoimmune or inflammatory conditions of the skin, as well as composition in the form of an ocular cream, gel or eye-drop preparation, e.g. for the purposes of application to the eye, and inhalable compositions, e.g., for use in treatment of autoimmune or inflammatory conditions of the lungs and airways.
- penetration enhancing agents e.g., for the treatment of autoimmune or inflammatory conditions of the skin
- an ocular cream, gel or eye-drop preparation e.g. for the purposes of application to the eye
- inhalable compositions e.g., for use in treatment of autoimmune or inflammatory conditions of the lungs and airways.
- Suitable surfactants include reaction products of natural or hydrogenated vegetable oils and ethylene glycol, e.g., polyethoxylated castor oils available for example under the trade mark CREMOPHOR (H.P. Fiedler, Lexikon der Hilfsstoffe fur Pharmazie, Kosmetik und angrenzende füre, Vol. 1, 3rd edition, 1989) e.g. CREMOPHOR RH 40 or EL; polyoxyethylene-glycerol- fatty acid esters, e.g. available under the trade mark TAGAT, e.g. TAGAT TO; and polyoxyethylene sorbitan fatty acid esters, e.g.
- a solid dispersion in the form of a simple eutectic mixture, solid solution or solid micellar solution, glass suspension or glass solution of active agent/complex association may be formed which contains the IL-2 transcription inhibitor, e.g. cyclosporin A, with 40-O-(2-hydroxyethyl)-rapamycin in fine to molecularly dispersed form.
- a solid dispersion is formed which is a co-precipitate of the H -2 transcription inhibitor, e.g. cyclosporin A, with 40-O-(2-hydroxyethyl)-rapamycin and a carrier medium e.g.
- the invention provides a pharmaceutical composition in the form of a microemulsion or a microemulsion preconcentrate, or a solid dispersion, e.g. as described herein, comprising (i) a rapamycin, e.g. rapamycin or 40-O-(2-hydroxyethyl)-rapamycin, and (ii) an IL-2 transcription inhibitor, e.g. cyclosporin A or FK 506, preferably in a synergistic ratio, e.g. as described above, for use in treatment or prevention of a condition as described above, e.g., the treatment or prevention of an autoimmune or inflammatory condition, or transplant rejection, especially chronic rejection or xenograft rejection, for example,
- a pharmaceutical composition in the form of a microemulsion or a microemulsion preconcentrate, or a solid dispersion, e.g. as described herein, comprising (i) a rapamycin, e.g. rapamycin or 40-
- Synergy is shown between the 40-O-(2-hydroxyethyl)-rapamycin and cyclosporin A in the two-way mouse mixed lymphocyte reaction.
- Spleen cells of BALB/c and CBA mice (1 x 10 from each strain) are cultured in duplicate in flat-bottom 96-well microtiter plates in the absence or presence of serially diluted compound in serum-free medium. After four days, 3 H-thymidine is added. Sixteen hours later, the cells are harvested and 3 H-thymidine incorporation is measured by liquid scintillation counting. Cell proliferation is assessed in the absence of compounds (100% value) or in the presence of serially diluted compounds or combinations of compounds.
- the maximum 3 H thymidine incorporation (100% value) is around 240 x 10 3 cpm, and the background 3 H-thymidine incorporation in unstimulated cells is around 5 x 10 3 cpm.
- Drug concentrations at which the maximum proliferative response is inhibited by 70% are calculated using a four- parameter logistic function.
- the IC 70 is 21 nM for cyclosporin A and 0.3 nM for 40-O-(2- hydroxyethyl)-rapamycin.
- EXAMPLE 2 Synergism between 40-O-(2-hydroxyethyl)-rapamycin and cyclosporin A in vivo
- Synergism in vivo is shown using orthotopic kidney and heterotopic heart allotransplantation models in male Lewis rats (RT1 ' haplotype) using donor organs from male DA rats (RTl a haplotype).
- the termination point in long term survivors is 100 days.
- the graft is removed at autopsy, fixed in buffered formalin, and embedded in paraffin.
- Four micron thick sections stained with hematoxylin and eosin are read for signs of rejection and scored as "no rejection”, or “marginal”, “slight”, “moderate”, or “severe” cellular rejection based on the extent of mononuclear cell infiltration and damage to the parenchyma (tubules in the kidney, myocytes in the heart).
- Cyclosporin A (NEORAL) and/or 40-O-(2-hydroxyethyl)-rapamycin are given daily orally in a microemulsion preconcentrate vehicle. Allograft survival data and histology are presented in Table 1. The minimum effective dose of cyclosporine A giving long term allograft survival is 5.0 mg/kg body weight, with a slight rejection in graft histology. For 40-O-(2-hydroxyethyl)- rapamycin, a dose of 5.0 mg kg must be given for long term survival of a kidney allograft; this dose is not fully effective for heart allograft.
- a dose of 1.0 or 2.0 mg kg cyclosporin A is combined with dosages of 0.5, 1.0 or 2.0 mg/kg 40-O-(2-hydroxyethyl)-rapamycin.
- Long term survival of the kidney allograft is seen at the lowest dosages of both compound; long term survival of the heart allograft at 1.0 mg/kg of each compound.
- the histology of the long term surviving allografts is improved.
- the index of synergy for the kidney transplant model is about 0.3 (1.0 mg/kg cyclosporin A) to 0.5 (2.0 mg/kg cyclosporin A), and for heart transplant, ⁇ 0.5 (1.0 mg/kg cyclosporin A) and ⁇ 0.7 (2.0 mg kg cyclosporin A).
- the in vivo synergy of the compounds is even greater than would be predicted from the in vitro results.
- a soft gelatin capsule suitable for oral administration is prepared containing the following composition in a 500mg dosage
- the composition is stable and no precipitation is observed.
- Soft gelatin capsules suitable for oral administration are prepared containing the following compositions, each in a 500mg dosage
- a solid dispersion formulation is prepared containing the following components in parts by weight:
- the components are dissolved in a 1 : 1 absolute ethanol/acetone mixture.
- the solvents are evaporated and the resulting dry residue milled to a fine powder with mean particle size around 0.1 to 0.4 mm.
- the fine powder is tabletted or filled into hard capsules.
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SI9730389T SI0956034T1 (en) | 1996-07-30 | 1997-07-29 | Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxyethyl)-rapamycin |
EP97937526A EP0956034B1 (en) | 1996-07-30 | 1997-07-29 | Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxyethyl)-rapamycin |
AT97937526T ATE222502T1 (en) | 1996-07-30 | 1997-07-29 | COMBINATION PREPARATION WITH AN INHIBITANT EFFECT ON TRANSPLANT REJECTION, AUTOIMMUNE DISEASES AND INFLAMMATION, CONTAINING CYCLOSPORIN A AND 40-0-(2-HYDROXYETHYL)-RAPAMYCIN |
US09/230,618 US6239124B1 (en) | 1996-07-30 | 1997-07-29 | Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin |
NZ333657A NZ333657A (en) | 1996-07-30 | 1997-07-29 | A pharmaceutical composition comprising cyclosporin A and 40-O-(2-hydroxyethyl)-rapamycin |
AU40124/97A AU730781B2 (en) | 1996-07-30 | 1997-07-29 | Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxiethyl)-rapamycin |
JP50851398A JP3942641B2 (en) | 1996-07-30 | 1997-07-29 | Pharmaceutical composition for the treatment of transplant rejection, autoimmune disease or inflammatory condition comprising cyclosporin A and 40-O- (2-hydroxyethyl) -rapamycin |
DK01131018T DK1208847T3 (en) | 1996-07-30 | 1997-07-29 | Pharmaceuticals for the treatment of graft rejection as well as autoimmune or inflammatory conditions |
DE69714861T DE69714861T2 (en) | 1996-07-30 | 1997-07-29 | COMBINATION PRODUCT WITH AN INHIBITING EFFECT ON REPELLATION OF TRANSPLANTS, AUTOIMMUNE DISEASES AND INFLAMMATION, WHICH CONTAINS CYCLOSPORIN A AND 40-0- (2-HYDROXYETHYL) -RAPAMYCIN |
DK97937526T DK0956034T3 (en) | 1996-07-30 | 1997-07-29 | Pharmaceutical compositions for the treatment of graft rejection, autoimmune or inflammatory conditions comprising cyclosporin A and 40-O- (2-hydroxyethyl) -rapamycin |
CA2261666A CA2261666C (en) | 1996-07-30 | 1997-07-29 | Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxiethyl)-rapamycin |
HK00102877A HK1023720A1 (en) | 1996-07-30 | 2000-05-15 | Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxyethyl)-rapamycin |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9615942.1A GB9615942D0 (en) | 1996-07-30 | 1996-07-30 | Organic compounds |
GB9615942.1 | 1996-07-30 | ||
GB9705684.0 | 1997-03-18 | ||
GBGB9705684.0A GB9705684D0 (en) | 1997-03-18 | 1997-03-18 | Organic compounds |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/230,618 A-371-Of-International US6239124B1 (en) | 1996-07-30 | 1997-07-29 | Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin |
US09/758,301 Continuation US6455518B2 (en) | 1996-07-30 | 2001-01-11 | Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998004279A1 true WO1998004279A1 (en) | 1998-02-05 |
Family
ID=26309775
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1997/004123 WO1998004279A1 (en) | 1996-07-30 | 1997-07-29 | Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxiethyl)-rapamycin |
Country Status (15)
Country | Link |
---|---|
US (2) | US6239124B1 (en) |
EP (2) | EP0956034B1 (en) |
JP (2) | JP3942641B2 (en) |
AT (2) | ATE222502T1 (en) |
AU (1) | AU730781B2 (en) |
CA (1) | CA2261666C (en) |
CY (1) | CY2391B1 (en) |
DE (2) | DE69736750T2 (en) |
DK (2) | DK1208847T3 (en) |
ES (2) | ES2270948T3 (en) |
HK (1) | HK1023720A1 (en) |
NZ (1) | NZ333657A (en) |
PT (2) | PT956034E (en) |
SI (1) | SI1208847T1 (en) |
WO (1) | WO1998004279A1 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2786771A1 (en) * | 1998-12-07 | 2000-06-09 | Novartis Ag | PROCESS FOR THE STABILIZATION OF A POLY-ENE MACROLIDE AND PHARMACEUTICAL COMPOSITION CONTAINING SUCH A COMPOUND |
WO2000045834A2 (en) * | 1999-02-05 | 2000-08-10 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease |
WO2000067773A3 (en) * | 1999-05-10 | 2001-06-28 | Novartis Ag | Combinations of immunosupressive agents for the treatment or prevention of graft rejections |
WO2006095173A2 (en) | 2005-03-11 | 2006-09-14 | Biotica Technology Limited | Medical uses of 39-desmethoxyrapamycin and analogues thereof |
EP1967520A2 (en) | 2002-07-16 | 2008-09-10 | Biotica Technology Limited | Production of polyketides and other natural products |
US7648996B2 (en) | 2005-03-11 | 2010-01-19 | Biotica Technology Limited | 39-desmethoxy derivatives of rapamycin |
US7803808B2 (en) | 2004-08-11 | 2010-09-28 | Wyeth Llc | Production of polyketides and other natural products |
EP2258415A3 (en) * | 2001-09-10 | 2011-03-23 | Abbott Laboratories | Medical devices containing rapamycin analogs |
EP2255836A3 (en) * | 2001-09-10 | 2011-04-06 | Abbott Laboratories | Medical devices containing rapamycin analogs |
EP2583678A2 (en) | 2004-06-24 | 2013-04-24 | Novartis Vaccines and Diagnostics, Inc. | Small molecule immunopotentiators and assays for their detection |
WO2013093493A1 (en) | 2011-12-23 | 2013-06-27 | Biotica Technology Limited | Novel rapamycin analogue |
EP2671583A1 (en) * | 2011-01-31 | 2013-12-11 | Osaka University | Externally-used drug for treating skin disorder and method for producing same |
WO2018148508A1 (en) | 2017-02-10 | 2018-08-16 | Mount Tam Biotechnologies, Inc. | Rapamycin analog |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1033128T2 (en) * | 1993-09-28 | 2012-02-29 | Scherer Gmbh R P | Soft gelatin capsule manufacture |
US5858401A (en) * | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
EP0956034B1 (en) * | 1996-07-30 | 2002-08-21 | Novartis AG | Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxyethyl)-rapamycin |
US20030199425A1 (en) * | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
GB9825632D0 (en) * | 1998-11-23 | 1999-01-13 | Novartis Ag | Organic compounds |
DE60113145T2 (en) * | 2000-11-03 | 2006-06-22 | The University Of Manchester | SELECTIVE GLUCOCORTICOID RECEPTOR AGONISTS |
US20020127263A1 (en) * | 2001-02-27 | 2002-09-12 | Wenda Carlyle | Peroxisome proliferator-acitvated receptor gamma ligand eluting medical device |
US8741378B1 (en) | 2001-06-27 | 2014-06-03 | Advanced Cardiovascular Systems, Inc. | Methods of coating an implantable device |
US6641611B2 (en) * | 2001-11-26 | 2003-11-04 | Swaminathan Jayaraman | Therapeutic coating for an intravascular implant |
US20040137066A1 (en) * | 2001-11-26 | 2004-07-15 | Swaminathan Jayaraman | Rationally designed therapeutic intravascular implant coating |
US20080145402A1 (en) * | 2001-09-10 | 2008-06-19 | Abbott Cardiovascular Systems Inc. | Medical Devices Containing Rapamycin Analogs |
US20030054042A1 (en) * | 2001-09-14 | 2003-03-20 | Elaine Liversidge | Stabilization of chemical compounds using nanoparticulate formulations |
MXPA04003623A (en) * | 2001-10-19 | 2004-12-02 | Isotechnika Inc | Novel cyclosporin analog microemulsion preconcentrates. |
IL161522A0 (en) * | 2001-10-25 | 2004-09-27 | Atherogenics Inc | Compounds and methods for treating transplant rejection |
US6939376B2 (en) * | 2001-11-05 | 2005-09-06 | Sun Biomedical, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
US7682387B2 (en) * | 2002-04-24 | 2010-03-23 | Biosensors International Group, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
US7109169B2 (en) * | 2002-06-28 | 2006-09-19 | Hobai Ion A | Method for treating heart failure by inhibiting the sarcolemmal sodium/calcium exchange |
CA2497640C (en) * | 2002-09-06 | 2012-02-07 | Abbott Laboratories | Medical device having hydration inhibitor |
CA2498191C (en) * | 2002-09-18 | 2012-04-10 | Trustees Of The University Of Pennsylvania | Method of inhibiting choroidal neovascularization |
US8202530B2 (en) * | 2002-09-27 | 2012-06-19 | Advanced Cardiovascular Systems, Inc. | Biocompatible coatings for stents |
AR043504A1 (en) * | 2003-03-17 | 2005-08-03 | Novartis Ag | PHARMACEUTICAL COMPOSITIONS THAT INCLUDE RAPAMYCIN FOR THE TREATMENT OF INFLAMMATORY DISEASES |
US7160867B2 (en) * | 2003-05-16 | 2007-01-09 | Isotechnika, Inc. | Rapamycin carbohydrate derivatives |
BRPI0414000B8 (en) * | 2003-08-29 | 2021-05-25 | Lifecycle Pharma As | Solid oral extended-release pharmaceutical composition containing tacrolimus in the form of a solid dispersion, dosage form, and use of the pharmaceutical composition |
AU2004274026A1 (en) | 2003-09-18 | 2005-03-31 | Macusight, Inc. | Transscleral delivery |
US8709469B2 (en) | 2004-06-30 | 2014-04-29 | Abbott Cardiovascular Systems Inc. | Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device |
US8021849B2 (en) * | 2004-11-05 | 2011-09-20 | Siemens Healthcare Diagnostics Inc. | Methods and kits for the determination of sirolimus in a sample |
EP1853259A1 (en) | 2005-02-09 | 2007-11-14 | Macusight, Inc. | Formulations for ocular treatment |
US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
WO2006089312A2 (en) * | 2005-02-15 | 2006-08-24 | Wyeth | Orally bioavailable cci-779 tablet formulations |
US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
HUE038768T2 (en) | 2005-02-18 | 2018-11-28 | Abraxis Bioscience Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
JP2008533204A (en) * | 2005-03-21 | 2008-08-21 | マクサイト, インコーポレイテッド | Drug delivery system for treatment of disease or condition |
CA2603084A1 (en) | 2005-04-12 | 2006-10-19 | Elan Pharma International Limited | Nanoparticulate and controlled release compositions comprising cyclosporine |
US7189582B2 (en) * | 2005-04-27 | 2007-03-13 | Dade Behring Inc. | Compositions and methods for detection of sirolimus |
WO2006119130A2 (en) * | 2005-04-29 | 2006-11-09 | Atrium Medical Corporation | Drug delivery coating for use with a medical device and methods of treating vascular injury |
US20080021078A1 (en) * | 2006-07-18 | 2008-01-24 | Horizon Therapeutics, Inc. | Methods and medicaments for administration of ibuprofen |
US20080020040A1 (en) * | 2006-07-18 | 2008-01-24 | Horizon Therapeutics, Inc. | Unit dose form for administration of ibuprofen |
US8067451B2 (en) | 2006-07-18 | 2011-11-29 | Horizon Pharma Usa, Inc. | Methods and medicaments for administration of ibuprofen |
WO2007012019A2 (en) * | 2005-07-18 | 2007-01-25 | Horizon Therapeutics, Inc. | Medicaments containing famotidine and ibuprofen and administration of same |
WO2007092620A2 (en) | 2006-02-09 | 2007-08-16 | Macusight, Inc. | Stable formulations, and methods of their preparation and use |
AU2007230964B2 (en) | 2006-03-23 | 2012-07-19 | Santen Pharmaceutical Co., Ltd. | Formulations and methods for vascular permeability-related diseases or conditions |
US8067033B2 (en) | 2007-11-30 | 2011-11-29 | Horizon Pharma Usa, Inc. | Stable compositions of famotidine and ibuprofen |
WO2008027963A2 (en) * | 2006-08-31 | 2008-03-06 | Horizon Therapeutics, Inc. | Nsaid dose unit formulations with h2-receptor antagonists and methods of use |
US8661630B2 (en) | 2008-05-21 | 2014-03-04 | Abbott Cardiovascular Systems Inc. | Coating comprising an amorphous primer layer and a semi-crystalline reservoir layer |
DE102008060549A1 (en) | 2008-12-04 | 2010-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Drug-peptide construct for extracellular accumulation |
US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
MX369728B (en) | 2010-03-29 | 2019-11-20 | Abraxis Bioscience Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents. |
CA2793974A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Methods of treating cancer |
US8685433B2 (en) | 2010-03-31 | 2014-04-01 | Abbott Cardiovascular Systems Inc. | Absorbable coating for implantable device |
CN106924219A (en) | 2010-06-04 | 2017-07-07 | 阿布拉科斯生物科学有限公司 | The method for treating cancer of pancreas |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
US8809562B2 (en) | 2011-06-06 | 2014-08-19 | Chevron Phillips Chemical Company Lp | Use of metallocene compounds for cancer treatment |
US9220759B2 (en) | 2012-02-23 | 2015-12-29 | Abbott Cardiovascular Systems Inc. | Treatment of diabetic patients with a drug eluting stent and adjunctive therapy |
US9220584B2 (en) | 2012-03-30 | 2015-12-29 | Abbott Cardiovascular Systems Inc. | Treatment of diabetic patients with a stent and locally administered adjunctive therapy |
EP2705856A1 (en) | 2012-09-07 | 2014-03-12 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. | Compounds for the treatment of neurodegenerative disorders |
ES2797376T3 (en) | 2013-01-24 | 2020-12-02 | Palvella Therapeutics Inc | Compositions for the transdermal administration of mTOR inhibitors |
BR112016006378A2 (en) | 2013-09-24 | 2017-08-01 | Giner Inc | gas treatment system for a cell implant |
US20170246187A1 (en) | 2014-08-28 | 2017-08-31 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
WO2016033556A1 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS |
EP3371590A4 (en) * | 2015-11-06 | 2019-07-10 | The Trustees of Columbia University in the City of New York | Exosomal protein profiling for detection of cardiac transplant rejection |
CA3043468C (en) | 2016-11-15 | 2021-06-22 | Giner Life Sciences, Inc. | Percutaneous gas diffusion device suitable for use with a subcutaneous implant |
JP2020503269A (en) | 2016-11-28 | 2020-01-30 | リポカイン インコーポレーテッド | Oral testosterone undecanoate therapy |
EP3565520A4 (en) | 2017-01-06 | 2020-08-19 | Palvella Therapeutics, Inc. | Anhydrous compositions of mtor inhibitors and methods of use |
EP3618916A4 (en) | 2017-05-04 | 2021-04-14 | Giner Life Sciences, Inc. | Robust, implantable gas delivery device and methods, systems and devices including same |
WO2020010073A1 (en) | 2018-07-02 | 2020-01-09 | Palvella Therapeutics, Inc. | ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0401747A2 (en) * | 1989-06-06 | 1990-12-12 | Roy Calne | Use of rapamycin and derivatives and prodrugs thereof in the manufacture of a medicament for inhibiting transplant rejection in mammals |
WO1994009010A1 (en) * | 1992-10-09 | 1994-04-28 | Sandoz Ltd. | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
WO1997025977A1 (en) * | 1996-01-19 | 1997-07-24 | Novartis Ag | Pharmaceutical compositions |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4894366A (en) | 1984-12-03 | 1990-01-16 | Fujisawa Pharmaceutical Company, Ltd. | Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same |
US5286731A (en) | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory bowel disease |
US5286730A (en) * | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory disease |
DE69302945T2 (en) | 1992-03-27 | 1996-10-10 | American Home Prod | 29-Demethoxyrapamycin for induction of immunosuppression |
GB2278780B (en) | 1993-05-27 | 1998-10-14 | Sandoz Ltd | Macrolide formulations |
GB9606452D0 (en) | 1996-03-27 | 1996-06-05 | Sandoz Ltd | Organic compounds |
EP0956034B1 (en) * | 1996-07-30 | 2002-08-21 | Novartis AG | Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxyethyl)-rapamycin |
EP1980263A1 (en) * | 1999-05-10 | 2008-10-15 | Novartis AG | Combinations of immunosuppressive agents for the treatment or prevention of graft rejections |
-
1997
- 1997-07-29 EP EP97937526A patent/EP0956034B1/en not_active Expired - Lifetime
- 1997-07-29 AT AT97937526T patent/ATE222502T1/en active
- 1997-07-29 SI SI9730756T patent/SI1208847T1/en unknown
- 1997-07-29 NZ NZ333657A patent/NZ333657A/en not_active IP Right Cessation
- 1997-07-29 PT PT97937526T patent/PT956034E/en unknown
- 1997-07-29 PT PT01131018T patent/PT1208847E/en unknown
- 1997-07-29 WO PCT/EP1997/004123 patent/WO1998004279A1/en active IP Right Grant
- 1997-07-29 JP JP50851398A patent/JP3942641B2/en not_active Expired - Lifetime
- 1997-07-29 DK DK01131018T patent/DK1208847T3/en active
- 1997-07-29 DE DE69736750T patent/DE69736750T2/en not_active Expired - Lifetime
- 1997-07-29 ES ES01131018T patent/ES2270948T3/en not_active Expired - Lifetime
- 1997-07-29 US US09/230,618 patent/US6239124B1/en not_active Expired - Lifetime
- 1997-07-29 AT AT01131018T patent/ATE340586T1/en active
- 1997-07-29 AU AU40124/97A patent/AU730781B2/en not_active Expired
- 1997-07-29 CA CA2261666A patent/CA2261666C/en not_active Expired - Lifetime
- 1997-07-29 ES ES97937526T patent/ES2182112T3/en not_active Expired - Lifetime
- 1997-07-29 DK DK97937526T patent/DK0956034T3/en active
- 1997-07-29 EP EP01131018A patent/EP1208847B8/en not_active Expired - Lifetime
- 1997-07-29 DE DE69714861T patent/DE69714861T2/en not_active Expired - Lifetime
-
2000
- 2000-05-15 HK HK00102877A patent/HK1023720A1/en not_active IP Right Cessation
-
2001
- 2001-01-11 US US09/758,301 patent/US6455518B2/en not_active Expired - Lifetime
-
2003
- 2003-11-28 CY CY0300086A patent/CY2391B1/en unknown
- 2003-12-08 JP JP2003408898A patent/JP4149905B2/en not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0401747A2 (en) * | 1989-06-06 | 1990-12-12 | Roy Calne | Use of rapamycin and derivatives and prodrugs thereof in the manufacture of a medicament for inhibiting transplant rejection in mammals |
WO1994009010A1 (en) * | 1992-10-09 | 1994-04-28 | Sandoz Ltd. | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
WO1997025977A1 (en) * | 1996-01-19 | 1997-07-24 | Novartis Ag | Pharmaceutical compositions |
Non-Patent Citations (3)
Title |
---|
SCHULER W. ET AL: "SDZ-RAD, A NEW RAPAMYCIN DERIVATIVE. Pharmacological properties in vitro and in vivo", TRANSPLANTATION, vol. 64, no. 1, 15 July 1997 (1997-07-15), pages 36 - 42, XP002048032 * |
SHUURMAN H.J. ET AL: "SDZ-RAD, A NEW RAPAMYCIN DERIVATIVE. SYNERGISM WITH CYCLOSPORINE", TRANSPLANTATION, vol. 64, no. 1, 15 July 1997 (1997-07-15), pages 32 - 35, XP002048030 * |
TU Y. ET AL: "The synergistic effects of cyclosporine, sirolimus, and brequinar on heart allograft survival in mice", TRANSPLANTATION, 1995, 59/2 (177-183), USA, XP002048031 * |
Cited By (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7741338B2 (en) | 1998-12-07 | 2010-06-22 | Novartis Ag | Macrolides |
WO2000033878A3 (en) * | 1998-12-07 | 2000-11-02 | Novartis Ag | Stabilization of macrolides |
US7572804B2 (en) | 1998-12-07 | 2009-08-11 | Novartis Ag | Macrolides |
EP2269651A3 (en) * | 1998-12-07 | 2011-03-09 | Novartis AG | Stabilisation of macrolides |
EP2279751A3 (en) * | 1998-12-07 | 2011-02-16 | Novartis AG | Stabilisation of macrolides |
BE1012869A3 (en) * | 1998-12-07 | 2001-04-03 | Novartis Ag | Stabilization method of poly-ene macrolide and pharmaceutical composition containing a compound tel. |
EP2279751A2 (en) * | 1998-12-07 | 2011-02-02 | Novartis AG | Stabilisation of macrolides |
EP2269651A2 (en) * | 1998-12-07 | 2011-01-05 | Novartis AG | Stabilisation of macrolides |
US6605613B2 (en) | 1998-12-07 | 2003-08-12 | Novartis Ag | Macrolides |
US6852729B2 (en) | 1998-12-07 | 2005-02-08 | Novartis Ag | Macrolides |
WO2000033878A2 (en) * | 1998-12-07 | 2000-06-15 | Novartis Ag | Stabilization of macrolides |
EP1743657A2 (en) * | 1998-12-07 | 2007-01-17 | Novartis AG | Stabilisation of macrolides |
EP1743657A3 (en) * | 1998-12-07 | 2007-03-28 | Novartis AG | Stabilisation of macrolides |
US7297703B2 (en) | 1998-12-07 | 2007-11-20 | Novartis Ag | Macrolides |
FR2786771A1 (en) * | 1998-12-07 | 2000-06-09 | Novartis Ag | PROCESS FOR THE STABILIZATION OF A POLY-ENE MACROLIDE AND PHARMACEUTICAL COMPOSITION CONTAINING SUCH A COMPOUND |
WO2000045834A3 (en) * | 1999-02-05 | 2000-12-21 | Univ Pittsburgh | Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease |
US8158110B2 (en) | 1999-02-05 | 2012-04-17 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease |
WO2000045834A2 (en) * | 1999-02-05 | 2000-08-10 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease |
JP2002544167A (en) * | 1999-05-10 | 2002-12-24 | ノバルティス アクチエンゲゼルシャフト | Organic compounds |
EP1980263A1 (en) * | 1999-05-10 | 2008-10-15 | Novartis AG | Combinations of immunosuppressive agents for the treatment or prevention of graft rejections |
US8435520B2 (en) | 1999-05-10 | 2013-05-07 | Paolo Brenner | Combinations of immunosuppressive agents for the treatment or prevention of graft rejections |
WO2000067773A3 (en) * | 1999-05-10 | 2001-06-28 | Novartis Ag | Combinations of immunosupressive agents for the treatment or prevention of graft rejections |
EP2255836A3 (en) * | 2001-09-10 | 2011-04-06 | Abbott Laboratories | Medical devices containing rapamycin analogs |
US10058641B2 (en) | 2001-09-10 | 2018-08-28 | Abbott Laboratories | Medical devices containing rapamycin analogs |
EP2258415A3 (en) * | 2001-09-10 | 2011-03-23 | Abbott Laboratories | Medical devices containing rapamycin analogs |
EP2277898A2 (en) | 2002-07-16 | 2011-01-26 | Biotica Technology Limited | Rapamycin analogues |
EP1967520A2 (en) | 2002-07-16 | 2008-09-10 | Biotica Technology Limited | Production of polyketides and other natural products |
EP2583678A2 (en) | 2004-06-24 | 2013-04-24 | Novartis Vaccines and Diagnostics, Inc. | Small molecule immunopotentiators and assays for their detection |
US7803808B2 (en) | 2004-08-11 | 2010-09-28 | Wyeth Llc | Production of polyketides and other natural products |
US8008318B2 (en) | 2005-03-11 | 2011-08-30 | Biotica Technology Limited | 39-desmethoxy derivatives of rapamycin |
WO2006095173A2 (en) | 2005-03-11 | 2006-09-14 | Biotica Technology Limited | Medical uses of 39-desmethoxyrapamycin and analogues thereof |
US7648996B2 (en) | 2005-03-11 | 2010-01-19 | Biotica Technology Limited | 39-desmethoxy derivatives of rapamycin |
EP2671583A1 (en) * | 2011-01-31 | 2013-12-11 | Osaka University | Externally-used drug for treating skin disorder and method for producing same |
EP2671583A4 (en) * | 2011-01-31 | 2014-09-03 | Univ Osaka | Externally-used drug for treating skin disorder and method for producing same |
WO2013093493A1 (en) | 2011-12-23 | 2013-06-27 | Biotica Technology Limited | Novel rapamycin analogue |
WO2018148508A1 (en) | 2017-02-10 | 2018-08-16 | Mount Tam Biotechnologies, Inc. | Rapamycin analog |
Also Published As
Publication number | Publication date |
---|---|
AU730781B2 (en) | 2001-03-15 |
ES2182112T3 (en) | 2003-03-01 |
ATE340586T1 (en) | 2006-10-15 |
JP3942641B2 (en) | 2007-07-11 |
DE69736750D1 (en) | 2006-11-09 |
EP1208847B1 (en) | 2006-09-27 |
HK1023720A1 (en) | 2000-09-22 |
US20010008888A1 (en) | 2001-07-19 |
DE69714861D1 (en) | 2002-09-26 |
US6239124B1 (en) | 2001-05-29 |
JP2004210767A (en) | 2004-07-29 |
AU4012497A (en) | 1998-02-20 |
DE69714861T2 (en) | 2003-05-22 |
JP4149905B2 (en) | 2008-09-17 |
EP0956034B1 (en) | 2002-08-21 |
EP1208847B8 (en) | 2007-02-14 |
ES2270948T3 (en) | 2007-04-16 |
PT956034E (en) | 2002-12-31 |
JP2000505806A (en) | 2000-05-16 |
CA2261666A1 (en) | 1998-02-05 |
NZ333657A (en) | 2000-05-26 |
EP1208847A3 (en) | 2002-06-12 |
DK1208847T3 (en) | 2007-01-08 |
DE69736750T2 (en) | 2007-08-16 |
EP1208847A2 (en) | 2002-05-29 |
DK0956034T3 (en) | 2002-12-16 |
US6455518B2 (en) | 2002-09-24 |
PT1208847E (en) | 2007-07-24 |
CA2261666C (en) | 2010-09-14 |
EP0956034A1 (en) | 1999-11-17 |
CY2391B1 (en) | 2004-09-10 |
ATE222502T1 (en) | 2002-09-15 |
SI1208847T1 (en) | 2007-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU730781B2 (en) | Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxiethyl)-rapamycin | |
TW404837B (en) | Cyclosporin compositions | |
US6565859B1 (en) | Galenical formulations | |
KR100452004B1 (en) | Rapamycin formulation for oral administration | |
EP0787011B1 (en) | microemulsion preconcentrate comprising a macrolide | |
EP1152750B1 (en) | Spontaneously dispersible n-benzoyl staurosporine compositions | |
JP2004107350A (en) | Pharmaceutical composition | |
BRPI0212922B1 (en) | PHARMACEUTICAL COMPOSITION IN THE FORM OF A DISPERSABLE TABLET UNDERSTANDING A SOLID 40-O- (2-HYDROXIETIL) DISPOSITION, ITS PROCESS FOR PREPARING AND USING DIET COMPOSITION | |
JPH07149656A (en) | Orally administerable rapamycin pharmaceutical preparation | |
RU2292887C2 (en) | Pharmaceutical composition, using carboxylic acid for stabilizing macrolide in this composition and method for stabilizing macrolide | |
RU2181054C2 (en) | Microemulsion preconcentrate | |
KR20200134271A (en) | Immunosuppressive dosage form and method of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1997937526 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 333657 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2261666 Country of ref document: CA Ref country code: CA Ref document number: 2261666 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09230618 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1997937526 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1997937526 Country of ref document: EP |